<DOC>
	<DOCNO>NCT00171873</DOCNO>
	<brief_summary>Placebo-controlled prospective randomize phase III study investigate antiproliferative effect octreotide patient metastasize neuroendocrine tumor midgut</brief_summary>
	<brief_title>Study Investigate Antiproliferative Effect Octreotide Patients With Metastasized Neuroendocrine Tumors Midgut</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Therapynaive patient histologically confirm diagnosis locally inoperable metastasize welldifferentiated neuroendocrine tumor midgut curative surgery impossible twodimensional tumor formation assessable Computed Tomography ( CT ) Magnetic Resonance Imaging ( MRI ) Age â‰¥ 18 Karnofskyindex &gt; 60 write informed consent proliferation index Ki67 hypersensitivity octreotide poorly differentiate small cell neuroendocrine tumor primary tumor outside midgut prior treatment somatostatinanalogue &gt; 4 week prior treatment alphainterferon , chemotherapy , chemoembolisation participation clinical trial pregnancy lactation secondary malignancy anamnesis ; exception patient without manifestation secondary malignancy ( without relapse ) curative therapy within last five year severe decompensated organ malfunction ( heart , liver insufficiency ) Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Double blind</keyword>
	<keyword>Phase III</keyword>
	<keyword>Disease</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Octreotide</keyword>
	<keyword>Neuroendocrine tumor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Midgut</keyword>
</DOC>